FDA approves Novo's Tresiba, Ryzodeg

FDA approved both Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart from Novo Nordisk A/S (NYSE:NVO; CSE:NVO) to improve glycemic control in adults with Types I and II diabetes.

Novo spokesperson Ken Inchausti told BioCentury Tresiba would launch in early 2016; a launch timeline has not been set for Ryzodeg. Inchausti said prices would not be available "for a few weeks." ...